311 related articles for article (PubMed ID: 36232843)
1. Oligonucleotide-Recognizing Topoisomerase Inhibitors (OTIs): Precision Gene Editors for Neurodegenerative Diseases?
Bax BD; Sutormin D; McDonald NQ; Burley GA; Shelkovnikova T
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232843
[TBL] [Abstract][Full Text] [Related]
2. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
4. Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases.
Singh S; Pandey VP; Yadav K; Yadav A; Dwivedi UN
Curr Protein Pept Sci; 2020; 21(11):1103-1142. PubMed ID: 32951576
[TBL] [Abstract][Full Text] [Related]
5. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
6. The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I.
Gentry AC; Juul S; Veigaard C; Knudsen BR; Osheroff N
Nucleic Acids Res; 2011 Feb; 39(3):1014-22. PubMed ID: 20855291
[TBL] [Abstract][Full Text] [Related]
7. Recognition of DNA Supercoil Handedness during Catenation Catalyzed by Type II Topoisomerases.
Dalvie ED; Stacy JC; Neuman KC; Osheroff N
Biochemistry; 2022 Oct; 61(19):2148-2158. PubMed ID: 36122251
[TBL] [Abstract][Full Text] [Related]
8. DNA Topoisomerases.
Bush NG; Evans-Roberts K; Maxwell A
EcoSal Plus; 2015; 6(2):. PubMed ID: 26435256
[TBL] [Abstract][Full Text] [Related]
9. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
You F; Gao C
Curr Top Med Chem; 2019; 19(9):713-729. PubMed ID: 30931860
[TBL] [Abstract][Full Text] [Related]
11. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
12. Sequence-specific base pair mimics are efficient topoisomerase IB inhibitors.
Vekhoff P; Duca M; Guianvarc'h D; Benhida R; Arimondo PB
Biochemistry; 2012 Jan; 51(1):43-51. PubMed ID: 22124209
[TBL] [Abstract][Full Text] [Related]
13. [DNA supercoiling and topoisomerases in Escherichia coli].
Gómez-Eichelmann MC; Camacho-Carranza R
Rev Latinoam Microbiol; 1995; 37(3):291-304. PubMed ID: 8850348
[TBL] [Abstract][Full Text] [Related]
14. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
McClendon AK; Osheroff N
Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
[TBL] [Abstract][Full Text] [Related]
15. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks.
McClendon AK; Rodriguez AC; Osheroff N
J Biol Chem; 2005 Nov; 280(47):39337-45. PubMed ID: 16188892
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Cartei G; Trestin A; Colombrino E; Nadai M; Richter SN; Barzon L; Palù G; Palumbo M;
Ann Oncol; 2006 May; 17 Suppl 5():v25-28. PubMed ID: 16807458
[TBL] [Abstract][Full Text] [Related]
17. Spatial organization of topoisomerase I-mediated DNA cleavage induced by camptothecin-oligonucleotide conjugates.
Arimondo PB; Angenault S; Halby L; Boutorine A; Schmidt F; Monneret C; Garestier T; Sun JS; Bailly C; Hélène C
Nucleic Acids Res; 2003 Jul; 31(14):4031-40. PubMed ID: 12853620
[TBL] [Abstract][Full Text] [Related]
18. Interaction in vitro of type III intermediate filament proteins with supercoiled plasmid DNA and modulation of eukaryotic DNA topoisomerase I and II activities.
Li G; Tolstonog GV; Sabasch M; Traub P
DNA Cell Biol; 2002 Oct; 21(10):743-69. PubMed ID: 12443544
[TBL] [Abstract][Full Text] [Related]
19. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Tse-Dinh YC
Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
[TBL] [Abstract][Full Text] [Related]
20. International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents.
Anderson RD; Berger NA
Mutat Res; 1994 Aug; 309(1):109-42. PubMed ID: 7519727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
